Janssen
J&J uses FDA Priority Review Voucher to snag psoriasis approval
July 14, 2017Medical Communications, Sales and Marketing Janssen, Johnson & Johnson, Tremfya, biotech, drugs, pharma, pharmaceutical
The FDA has handed out another approval, as the agency now easily surpasses last year’s figure of 22 already, this …
Making strides in hepatitis
June 19, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Johnson & Johnson
Pharmafocus caughtup with Lawrence Blatt, Janssen’s Global Therapeutic Area Head, Infectious Diseases and Vaccines, to discuss the progress being made in the …
J&J lines up its Global Head for Actelion
May 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Janssen, Johnson & Johnson
The deal is not yet complete but the last steps are assumed to be a formality – at least Johnson …
NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara
May 3, 2017Research and Development, Sales and Marketing Crohn’s disease, Janssen, NICE, Stelara, crohn's disease
Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely …
Janssen scores EU approval for blood cancer drug Darzalex
May 2, 2017Manufacturing and Production, Sales and Marketing Europe, European Commission, Janssen, darzalex
Janssen has announced that its CD38-directed monoclonal antibody Darzalex (daratumumab) has expanded its indication with a thumbs-up from the European …
Janssen acquires over 90% of Actelion
April 24, 2017Sales and Marketing Actelion, Janssen
Actelion has revealed that, following the wrap of its $30 billion deal in January, Janssen Holding has acquired 92.51% of …
Phase 3 data for Janssen psoriasis drug shows efficacy over Humira
March 6, 2017Research and Development, Sales and Marketing Humira, Janssen, guselkumab, psoriasis
Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate …
EMA recommends expanded indication for Janssen multiple myeloma drug
February 27, 2017Manufacturing and Production, Research and Development, Sales and Marketing Janssen, darzalex
The European Medicines Agency’s Committee for Medicinal Products for Human Use has given its positive opinion for the use of …
Bayer’s cardiovascular drug races to target in trial
February 9, 2017Research and Development, Sales and Marketing Bayer, Janssen, Xarelto
Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it …
NICE approves Imbruvica for second-line leukaemia treatment
January 26, 2017Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica
NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …
J&J finally seals $30 billion deal for Actelion
January 26, 2017Sales and Marketing Actelion, Janssen, Johnson & Johnson
Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working …
SMC rejects Janssen’s multiple myeloma treatment Darzalex
January 17, 2017Manufacturing and Production, Sales and Marketing Janssen, SMC, darzalex
The Scottish Medicines Consortium (SMC) has decided not to recommend Janssen’s Darzalex (daratumumab) for routine use by NHS Scotland as …
Advancing the Pharmaceutical Supply Chain
January 13, 2017Manufacturing and Production, Medical Communications Janssen, batch manufacturing, continuous manufacturing
Mauricio Futran, vice president, Process Sciences, Janssen Supply Chain, discusses, in the latest issue of Pharmafile, Janssen’s move into continuous …
Five major pharma firms break ABPI code of conduct, according to watchdog
December 15, 2016Medical Communications, Sales and Marketing ABPI, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Grunenthal, Janssen
Eli Lilly, Boehgringer Ingelheim, AstraZeneca UK, Grunenthal and Janssen-Cilag have been “named and shamed” by the Prescription Medicines Code of …
Janssen reveals positive results from longest follow-up of Imbruvica
December 7, 2016Research and Development AbbVie, Cilag, Janssen, Pharmacyclics, imbruvica
Janssen used the 5th Annual American Society of Hematoly Meeting and Exposition to reveal that a five-year study of Imbruvica …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
